Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.6% – Time to Sell?

Eli Lilly and Company (NYSE:LLY)’s stock price dropped 2.6% during mid-day trading on Thursday . The company traded as low as $1,243.23 and last traded at $1,246.89. Approximately 2,317,653 shares were traded during mid-day trading, a decline of 25% from the average session volume of 3,107,601 shares. The stock had previously closed at $1,280.34.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity-drug leadership remains the main catalyst. Recent coverage says Lilly’s GLP-1 portfolio is outpacing Novo Nordisk’s in the latest quarter, while demand for its obesity treatments remains strong. Investors are also focused on oral GLP-1 candidates and retatrutide, which could expand Lilly’s addressable market. How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
• Positive Sentiment: Pipeline activity continues across multiple therapeutic areas. Lilly reported progress in early-stage studies for LY4178256, eloralintide, lepodisiran and oral candidate LY4065967. Completion of a Phase 3 lebrikizumab trial also supports a potential growth opportunity in atopic dermatitis, although most updates remain too early to affect near-term earnings. Lilly’s Lebrikizumab Trial Completion Signals New Growth Path
• Positive Sentiment: Fundamentals remain supportive. Lilly’s latest quarter exceeded expectations, with revenue rising 47.7% year over year, reinforcing the investment case for continued GLP-1-driven growth. Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?
• Neutral Sentiment: Manufacturing investment is advancing. Lilly disclosed construction and traffic-management plans for its Lehigh Valley project, indicating progress on capacity expansion but no immediate change to earnings expectations. Eli Lilly Reveals Lehigh Valley Construction Plans
• Negative Sentiment: Valuation and competitive risk may be driving profit-taking. After a sharp post-earnings rally and record highs, Lilly trades at a demanding earnings multiple. Investors must also assess Novo Nordisk’s lead in oral obesity treatments and the potential entry of additional competitors.
• Negative Sentiment: Insider selling adds a modest sentiment headwind. EVP Patrik Jonsson sold 6,500 shares for about $7.6 million, though the transaction was executed under a pre-arranged Rule 10b5-1 plan, limiting its bearish significance. SEC Insider Transaction Filing

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. Morgan Stanley reissued an “overweight” rating and set a $1,419.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. BMO Capital Markets reissued an “outperform” rating and set a $1,400.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 6th. Sanford C. Bernstein raised their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company Price Performance

The company’s 50-day moving average is $1,176.04 and its 200-day moving average is $1,056.96. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm has a market capitalization of $1.17 trillion, a price-to-earnings ratio of 41.84, a PEG ratio of 1.45 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 23.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last ninety days. Insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently modified their holdings of the company. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Basso Capital Management L.P. acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $30,000. Maseco LLP boosted its position in Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its position in Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. increased its holdings in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.